CCAAT enhancer-binding protein alpha (CEBPA) (CEBPA)

CCAAT enhancer-binding protein alpha (CEBPA) is a critical transcription factor belonging to the basic leucine zipper (bZIP) family, primarily known for its role in coordinating the balance between cell proliferation and terminal differentiation (UniProt P49715). It is a master regulator of myelopoiesis, essential for the development of granulocytes, and also plays a vital role in the metabolic regulation of hepatocytes and adipocytes (PubMed: 15133543). In clinical oncology, CEBPA is frequently associated with acute myeloid leukemia (AML), where mutations or epigenetic silencing lead to a block in myeloid maturation and the expansion of leukemic blasts (NCBI Gene: 1050). Therapeutic strategies targeting CEBPA include the use of small activating RNAs (saRNAs), such as MTL-CEBPA, which are designed to upregulate its expression and restore normal cellular differentiation (PubMed: 30104334). Beyond cancer, CEBPA is investigated for its potential in treating chronic liver diseases and metabolic disorders due to its influence on lipid and glucose homeostasis.

Other names

C/EBP alphaCEBPACCAAT/enhancer-binding protein alphaC/EBP-alphaTranscription factor C/EBP alpha

Upregulation of CEBPA expression through small activating RNA (saRNA) technology to promote myeloid differentiation and inhibit tumor growth, or indirect modulation via epigenetic modifiers to reverse gene silencing.